Virbac SA
PAR:VIRP
Virbac SA
Free Cash Flow
Virbac SA
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Virbac SA
PAR:VIRP
|
Free Cash Flow
€133.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
|
Sanofi SA
PAR:SAN
|
Free Cash Flow
€4.1B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
|
Ipsen SA
PAR:IPN
|
Free Cash Flow
€133m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-2%
|
|
|
Vetoquinol SA
PAR:VETO
|
Free Cash Flow
€70.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
27%
|
CAGR 10-Years
11%
|
|
|
Boiron SA
PAR:BOI
|
Free Cash Flow
€24.7m
|
CAGR 3-Years
22%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-8%
|
|
|
Medincell SA
PAR:MEDCL
|
Free Cash Flow
€20.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Virbac SA
Glance View
Founded in 1968 in the picturesque city of Carros near Nice, France, Virbac SA has grown to become a formidable player in the animal health industry. With its roots firmly planted in the niche of veterinary medicine, the company was established by Pierre-Richard Dick, a veterinarian himself, who sought to fill a gap in high-quality veterinary products. Today, Virbac stands as one of the largest independent veterinary pharmaceutical companies, with an extensive global presence spanning more than 100 countries. The company’s portfolio is diverse, encompassing products for both livestock and pets, including vaccines, antibiotics, and specialty diets designed to enhance animal health and welfare. By focusing on R&D and maintaining robust relationships with veterinary professionals, Virbac continually develops solutions that address the evolving needs of animal care. Virbac’s business model revolves around an intricate balance of innovation and strategic market expansion. The company's revenue streams derive from its comprehensive range of products aimed at disease prevention and treatment, which serve various species such as cattle, swine, poultry, horses, cats, and dogs. By investing significantly in research and development, Virbac not only stays ahead in terms of product efficacy and safety but also navigates the regulatory landscapes across its operating regions. This drive to innovate is coupled with a meticulous marketing strategy that involves educating veterinary professionals and end-users, ensuring the optimal use of their products. As a result, Virbac successfully generates income through the direct sale of its products to veterinary clinics, distributors, and directly to pet owners, continually reinforcing its role as a trusted partner in animal health care globally.
See Also
What is Virbac SA's Free Cash Flow?
Free Cash Flow
133.5m
EUR
Based on the financial report for Dec 31, 2024, Virbac SA's Free Cash Flow amounts to 133.5m EUR.
What is Virbac SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
14%
Over the last year, the Free Cash Flow growth was 100%. The average annual Free Cash Flow growth rates for Virbac SA have been 17% over the past three years , 4% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet